RT Journal Article
T1 Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
A1 Arenas, Maria Dolores
A1 Rodelo-Haad, Cristian
A1 Pendón-Ruiz de Mier, M Victoria
A1 Rodriguez, Mariano
K1 Adherence
K1 Calcium
K1 Cinacalcet
K1 Etelcalcetide
K1 PTH
K1 Adhesión celular
K1 Calcio
K1 Hormona paratiroidea
K1 Hiperparatiroidismo secundario
K1 Cumplimiento de la medicación
K1 Pacientes
K1 Diálisis
AB Background. In dialysis patients, non-adherence to oral cinacalcet adds complexity to the control of secondary hyperparathyroidism. The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics. Method. The Simplified Medication Adherence Questionnaire was used to identify non-adherence. Almost half of the patients were non-adherent to the treatment with cinacalcet. Twenty-five patients (15 non-adherent) were switched from cinacalcet to etelcalcetide and were followed-up monthly for 8 months. Results. Cinacalcet was discontinued for 1 week before the initiation of etelcalcetide. After this period, the serum PTH levels increased by2-fold in adherent patients, whereas it did not change in non-adherent patients suggesting that they were not taking the medication. Etelcalcetide progressively reduced serum parathyroid hormone (PTH) (mean 6 standard deviation) from 818 6 395 to 367 6 289 pg/mL (P< 0.001) in non-adherents, and from 496 6 172 to 228 6 111 pg/mL (P< 0.01) in adherent patients with a mean dose of 7.0 6 2.3 and 5.1 6 1.2 mg in non-adherent and in adherent patients, respectively. Etelcalcetide increased the percentage of patients with PTH on target from 28% to 58%. Patients with serum calcium <8.4 mg/dL increased from 8% to 40%, although they remained asymptomatic. The percent of patients with serum phosphate on target increased from 40% to 65%. Conclusion. The lack of adherence to cinacalcet is a possible cause of the apparent lack of response to oral calcimimetic.The use of etelcalcetide ensures compliance and control of secondary hyperparathyroidism in both non-adherent and adherent patients.
PB Oxford University Press
SN 2048-8505
YR 2020
FD 2020-02-12
LK http://hdl.handle.net/10668/4299
UL http://hdl.handle.net/10668/4299
LA en
NO Arenas MD, Rodelo-Haad C, Pendón-Ruiz de Mier MV, Rodriguez M. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics. Clin Kidney J. 2020 Feb 12;14(3):840-846
DS RISalud
RD Apr 12, 2025